| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |